Purpose Of Review: This review takes a look at the past, present, and future of SPARTAN, the Spondyloarthritis Research and Treatment Network, an organization of North American healthcare professionals dedicated to advancing research, education, and patient care in spondyloarthritis.
Recent Findings: In 2022, SPARTAN completed the Classification of Axial SpondyloarthritiS Inception Cohort (CLASSIC) study, a collaboration with the Assessment in SpondyloArthritis International Society (ASAS). CLASSIC aimed to validate the 2009 ASAS classification criteria for axial spondyloarthritis. Other ongoing SPARTAN endeavors include the development of US referral recommendations for axial spondyloarthritis, an update of the 2019 ACR/SAA/SPARTAN treatment recommendations for axial spondyloarthritis and multiple educational initiatives. Twenty years after its inception, SPARTAN continues to grow and broaden its impact, guided by the SPARTAN vision of "a world free of spondyloarthritis through leadership in research and education."
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11926-023-01131-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy.
RMD Open
January 2025
Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Charite Universitatsmedizin Berlin, Berlin, Germany.
Objectives: In this post-hoc analysis of ESTHER trial, we aimed to investigate the longitudinal relationship between inflammation on MRI and the achievement of inactive disease/low disease activity in patients with axial spondyloarthritis (axSpA) treated with long-term tumor necrosis factor (TNF) inhibitor etanercept.
Methods: Of the 76 patients with active axSpA in the ESTHER trial, we included all patients treated with etanercept for at least 6 months for main analysis. All clinical and MRI data from 4.
Exploration of molecular biomarkers in ankylosing spondylitis transcriptomics.
Front Immunol
January 2025
Research Center of Hyperuricemia and Gout, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China.
Article Synopsis
- Ankylosing spondylitis (AS) is a chronic condition characterized by inflammation of the spine and sacroiliac joints, leading to potential delays in diagnosis and treatment due to its non-specific early symptoms, underscoring the need for new biomarkers.
- Two datasets (GSE73754 and GSE25101) were analyzed to identify key genes related to AS, using methods like differential expression analysis and LASSO regression, which resulted in the discovery of five significant genes (ACSL1, SLC40A1, GZMM, TRIB1, XBP1) that showed strong diagnostic potential.
- The study also revealed correlations between these genes and immune cell infiltration as well as clinical indicators, with notable links between
Five Cases of Non-radiographic Spondyloarthritis (nr-SpA) of Patients from a Tertiary Care Center in the Philippines: A Case Series.
Acta Med Philipp
November 2024
Department of Medicine, Makati Medical Center.
Axial Spondyloarthritis (SpA) is a chronic inflammatory disease of the spine associated with the gene HLA-B27. Non-radiographic spondyloarthritis (nr-SpA), an early stage of axial SpA often goes unrecognized in many settings including the Philippines. We describe five Filipinos from a tertiary health care facility who fulfill the Assessment of SpondyloArthritis International Society (ASAS) 2009 criteria for non-radiographic SpA with the aim of increasing awareness of this disease in the Philippines.
View Article and Find Full Text PDFCelecoxib is the only nonsteroidal anti-inflammatory drug to inhibit bone progression in spondyloarthritis.
BMB Rep
January 2025
Division of Rheumatology, Regional Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon 35015, Korea.
Spondyloarthritis (SpA) is a chronic inflammatory disease that leads to ankylosis of the axial skeleton. Celecoxib (cyclooxygenase-2 inhibitor, COX-2i) inhibited radiographic progression in a clinical study of SpA, but in the following study, diclofenac (COX-2 non-selective) failed to show that inhibition. Our study aimed to investigate whether nonsteroidal anti-inflammatory drugs (NSAIDs) inhibited bone progression in SpA, and whether celecoxib had a unique function (independent of the COX-inhibitor), compared with the other NSAIDs.
View Article and Find Full Text PDF[The best preferable sagittal vertical axis for the ankylosis spondylitis with thoracolumbar kyphosis following one-level pedicle subtraction osteotomy under different cervical range of motion].
Zhonghua Yi Xue Za Zhi
January 2025
Division of Spine Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing210008, China.
To analyze the influence of cervical range of motion on the preferable sagittal vertical axis in ankylosis spondylitis (AS)-related thoracolumbar kyphosis following single-level pedicle subtraction osteotomy (PSO). The clinical data of sixty-five AS patients who underwent single-level PSO from February 2012 to November 2018 in the Drum Tower Hospital of Nanjing University Medical School were retrospectively reviewed. Of the patients, 59 were males and 6 were females with a mean age of (34.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!